Neurotech International Limited
Neurotech International Limited
Your view on NTI.AX
Overview
What the company does, where it operates, and who runs it.
About Neurotech International Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Anthony Filippis
- Headquarters
- 55 Collins Street, Melbourne, VI, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Anthony Filippis
- Headquarters
- 55 Collins Street, Melbourne, VI, AU
Neurotech International Limited (NTI.AX), along with its subsidiaries, is an Australian firm dedicated to the research, development, and manufacture of innovative medical devices and solutions. The company's primary focus lies in advancing and commercializing its Mente platform, a technological system designed to monitor and facilitate home-based therapies. This includes its Mente Autism product, specifically aimed at the diagnosis and treatment of autism spectrum disorder. Additionally, Neurotech actively undertakes various medical research projects and engineers new technological instruments. The company was established in 2016 and maintains its headquarters in Nedlands, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Neurotech International Limited, and the rating behind it. NTI.AX last traded at AUD 0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Neurotech International Limited. Starting points for Neurotech International Limited: EPS -AUD 0.07, beta 0.02 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Neurotech International Limited. Neurotech International Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Neurotech International Limited. Trailing twelve-month EPS for Neurotech International Limited stands at -AUD 0.07. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Neurotech International Limited. Neurotech International Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Neurotech International Limited valued side by side against its closest peers. Neurotech International Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Neurotech International Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Neurotech International Limited executives and directors. Shares of Neurotech International Limited have traded between AUD 0.01 and AUD 0.03 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Neurotech International Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Neurotech International Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Neurotech International Limited. Coverage tracks Neurotech International Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.